Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, Minnesota, USA.
Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
JPEN J Parenter Enteral Nutr. 2020 Feb;44(2):301-307. doi: 10.1002/jpen.1526. Epub 2019 Mar 12.
Although home parenteral nutrition (HPN) is lifesaving for patients with chronic intestinal failure (IF), long-term use can be associated with complications such as infections, metabolic abnormalities, and IF-associated liver disease (IFALD). The key to treatment of many of these complications is prevention. Guidelines recommend avoidance of overfeeding, use of oral/enteral nutrition if possible, cyclic PN, and maintaining dose of soybean oil (SO) intravenous lipid emulsion (ILE) <1 g/kg/day as preventive strategies for IFALD. Additionally, with development of IFALD, ω-6/ω-3 polyunsaturated fatty acid ratio should be decreased in ILE. The newly available mixed-oil (MO) ILE offers such an opportunity; however, there is a paucity of long-term data available.
The current study reports our long-term experience with MO ILE use in HPN patients.
Seventeen patients (8 female and 9 male) with an average age of 47 ± 12 years and median HPN duration of 4.6 years (1.1-32.1 years) have utilized MO ILE for >12 months after being transitioned from SO ILE because of intolerance. Use of MO ILE allowed an increase in ILE energy from 8% ± 8% to 22% ± 8% while reducing dextrose energy from 66% ± 8% to 54% ± 5%, maintaining stability in alkaline phosphatase and triglyceride levels, and achieving improvement in aspartate aminotransferase, alanine aminotransferase, total bilirubin, and α-tocopherol levels.
In this HPN cohort with SO ILE intolerance, MO ILE was well tolerated and allowed an improvement in macronutrient composition while improving some liver parameters over a 12-month period.
虽然家庭肠外营养(HPN)对慢性肠衰竭(IF)患者的生命至关重要,但长期使用可能会导致感染、代谢异常和 IF 相关肝病(IFALD)等并发症。许多这些并发症的治疗关键在于预防。指南建议避免过度喂养,如果可能的话使用口服/肠内营养,周期性 PN,并将大豆油(SO)静脉内脂肪乳剂(ILE)的剂量保持在<1g/kg/天,作为预防 IFALD 的策略。此外,随着 IFALD 的发展,ILE 中的ω-6/ω-3 多不饱和脂肪酸比例应降低。新出现的混合油(MO)ILE 提供了这样的机会;然而,目前缺乏长期数据。
本研究报告了我们在 HPN 患者中使用 MO ILE 的长期经验。
17 名患者(8 名女性和 9 名男性),平均年龄为 47±12 岁,中位 HPN 持续时间为 4.6 年(1.1-32.1 年),由于不耐受,从 SO ILE 转为 MO ILE 后,已使用 MO ILE 超过 12 个月。使用 MO ILE 可以将 ILE 能量从 8%±8%增加到 22%±8%,同时将葡萄糖能量从 66%±8%降低到 54%±5%,保持碱性磷酸酶和甘油三酯水平稳定,并实现天门冬氨酸氨基转移酶、丙氨酸氨基转移酶、总胆红素和α-生育酚水平的改善。
在本 SO ILE 不耐受的 HPN 队列中,MO ILE 耐受良好,并允许在 12 个月的时间内改善宏量营养素组成,同时改善一些肝脏参数。